CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Aripiprazole for Borderline Personality Disorder: A Review of the Clinical Effectiveness

Last updated: February 3, 2017
Project Number: RC0846-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary with Critical Appraisal
Result type: Report


  1. What is the clinical effectiveness of aripiprazole for the treatment of borderline personality disorder?

Key Message

The findings observed in two relatively small RCTs indicated that aripiprazole appears to be a safe and effective agent in the long term treatment of patients with borderline personality disorder. Similar clinical effectiveness and safety profiles were reported comparing aripiprazole with olanzapine in the treatment of BPD. However, due to the methodological limitations of the study design, whether the findings reported in the included RCTs could be generalized to Canadian routine clinical practice settings is uncertain and should be interpreted with caution.